Jump to section
IdentificationPharmacologyInteractionsReferencesTrialsEconomicsPropertiesSpectraTaxonomyMeclofenamic acid
Identification
- Name
- Meclofenamic acid
- Accession Number
- DB00939 (APRD01090)
- Type
- Small Molecule
- Groups
- Approved, Vet approved
- Description
A non-steroidal anti-inflammatory agent with antipyretic and antigranulation activities. It also inhibits prostaglandin biosynthesis. [PubChem]
- Structure
Structure for DB00939 (Meclofenamic acid)
- Synonyms
- Acide meclofenamique
- Acido meclofenamico
- Acidum meclofenamicum
- Meclofenamate
- N-(2,6-Dichloro-3-methylphenyl)anthranilic acid
- N-(2,6-Dichloro-m-tolyl)anthranilic acid
- N-(3-Methyl-2,6-dichlorophenyl)anthranilic acid
- External IDs
- CI 583 / CI-583 / Cl 583 / INF 4668 / INF-4668
- Product Ingredients
Ingredient UNII CAS InChI Key Meclofenamate sodium 94NJ818U2W 67254-91-5 QHJLLDJTVQAFAN-UHFFFAOYSA-M - Generic Prescription Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Meclofenamate Sodium Capsule 50 mg/1 Oral Mylan Pharmaceuticals 1986-09-03 Not applicable US 
Meclofenamate Sodium Capsule 100 mg/1 Oral Mylan Pharmaceuticals 1986-09-03 Not applicable US - International/Other Brands
- Ethos (Yung Shin) / Eucome (U-Liang) / Meclomen (Pfizer)
- Categories
- Acids, Carbocyclic
- Amines
- Aminobenzoates
- Analgesics
- Analgesics, Non-Narcotic
- Aniline Compounds
- Anti-Inflammatory Agents
- Anti-Inflammatory Agents, Non-Steroidal
- Antiinflammatory Preparations, Non-Steroids for Topical Use
- Antirheumatic Agents
- Benzene Derivatives
- Benzoates
- Central Nervous System Agents
- Cyclooxygenase Inhibitors
- Enzyme Inhibitors
- Fenamates
- Musculo-Skeletal System
- ortho-Aminobenzoates
- Peripheral Nervous System Agents
- Sensory System Agents
- Topical Products for Joint and Muscular Pain
- UNII
- 48I5LU4ZWD
- CAS number
- 644-62-2
- Weight
- Average: 296.149
Monoisotopic: 295.016684015 - Chemical Formula
- C14H11Cl2NO2
- InChI Key
- SBDNJUWAMKYJOX-UHFFFAOYSA-N
- InChI
- InChI=1S/C14H11Cl2NO2/c1-8-6-7-10(15)13(12(8)16)17-11-5-3-2-4-9(11)14(18)19/h2-7,17H,1H3,(H,18,19)
- IUPAC Name
- 2-[(2,6-dichloro-3-methylphenyl)amino]benzoic acid
- SMILES
- CC1=C(Cl)C(NC2=CC=CC=C2C(O)=O)=C(Cl)C=C1
Pharmacology
- Indication
For the relief of mild to moderate pain, for the treatment of primary dysmenorrhea and for the treatment of idiopathic heavy menstrual blood loss. Also for relief of the signs and symptoms of acute and chronic rheumatoid arthritis and osteoarthritis.
- Structured Indications
- Pharmacodynamics
Meclofenamic acid is a nonsteroidal agent which has demonstrated anti-inflammatory, analgesic, and antipyretic activity in laboratory animals.
- Mechanism of action
The mode of action, like that of other nonsteroidal anti-inflammatory agents, is not known. Therapeutic action does not result from pituitary-adrenal stimulation. In animal studies, meclofenamic acid was found to inhibit prostaglandin synthesis and to compete for binding at the prostaglandin receptor site. In vitro meclofenamic acid was found to be an inhibitor of human leukocyte 5-lipoxygenase activity. These properties may be responsible for the anti-inflammatory action of meclofenamic acid. There is no evidence that meclofenamic acid alters the course of the underlying disease.
Target Actions Organism AProstaglandin G/H synthase 1 inhibitorHuman AProstaglandin G/H synthase 2 inhibitorHuman AArachidonate 5-lipoxygenase inhibitorHuman UPotassium voltage-gated channel subfamily KQT member 2 otherHuman UPotassium voltage-gated channel subfamily KQT member 3 otherHuman - Absorption
Rapidly absorbed in man following single and multiple oral doses with peak plasma concentrations occurring in 0.5 to 2 hours. The concomitant administration of antacids (aluminum and magnesium hydroxides) does not interfere with absorption of meclofenamic acid. Unlike most NSAIDs, which when administered with food have a decrease in rate but not in extent of absorption, meclofenamic acid is decreased in both. It has been reported that following the administration of meclofenamic acid capsules one-half hour after a meal, the average extent of bioavailability decreased by 26%, the average peak concentration (Cmax) decreased fourfold and the time to Cmax was delayed by 3 hours.
- Volume of distribution
- 9.1 to 43.2 L
- Protein binding
Greater than 99% bound to plasma proteins over a wide drug concentration range.
- Metabolism
Hepatic. Meclofenamic acid is extensively metabolized to an active metabolite (Metabolite I; 3-hydroxymethyl metabolite of meclofenamic acid) and at least six other less well characterized minor metabolites. Only Metabolite I has been shown in vitro to inhibit cyclooxygenase activity with approximately one fifth the activity of meclofenamic acid.
- Route of elimination
Other metabolites, whose excretion rates are unknown, account for the remaining 35% to 62% of the dose excreted in the urine. The remainder of the administered dose (approximately 30%) is eliminated in the feces (apparently through biliary excretion). Trace amounts of meclofenamate sodium are excreted in human breast milk.
- Half life
In a study in 10 healthy subjects following a single oral dose the apparent elimination half-life ranged from 0.8 to 5.3 hours. Metabolite I (3-hydroxymethyl metabolite of meclofenamic acid) has a mean half-life of approximately 15 hours.
- Clearance
- Oral cl=206 mL/min
- Toxicity
After a massive overdose, CNS stimulation may be manifested by irrational behavior, marked agitation and generalized seizures. Following this phase, renal toxicity (falling urine output, rising creatinine, abnormal urinary cellular elements) may be noted with possible oliguria or anuria and azotemia. A 24 year-old male was anuric for approximately one week after ingesting an overdose of 6 to 7 grams of meclofenamate sodium. Spontaneous diuresis and recovery subsequently occurred.
- Affected organisms
- Humans and other mammals
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
Drug Interaction Drug group (4R)-limonene The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with (4R)-limonene. Investigational 16-Bromoepiandrosterone The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with 16-Bromoepiandrosterone. Investigational 19-norandrostenedione The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with 19-norandrostenedione. Experimental, Illicit 5-androstenedione The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with 5-androstenedione. Experimental, Illicit Abciximab Meclofenamic acid may increase the anticoagulant activities of Abciximab. Approved Acebutolol Meclofenamic acid may decrease the antihypertensive activities of Acebutolol. Approved, Investigational Aceclofenac The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Aceclofenac. Approved, Investigational Acemetacin The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Acemetacin. Approved, Experimental, Investigational Acenocoumarol Meclofenamic acid may increase the anticoagulant activities of Acenocoumarol. Approved, Investigational Acetylsalicylic acid The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Acetylsalicylic acid. Approved, Vet Approved Aclarubicin Meclofenamic acid may decrease the excretion rate of Aclarubicin which could result in a higher serum level. Investigational Adapalene The risk or severity of adverse effects can be increased when Adapalene is combined with Meclofenamic acid. Approved Alclofenac The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Alclofenac. Approved, Withdrawn Alclometasone The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Alclometasone. Approved Aldosterone The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Aldosterone. Experimental, Investigational Aldoxorubicin Meclofenamic acid may decrease the excretion rate of Aldoxorubicin which could result in a higher serum level. Investigational Alendronic acid The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Alendronic acid. Approved Aliskiren Meclofenamic acid may decrease the antihypertensive activities of Aliskiren. Approved, Investigational Alminoprofen The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Alminoprofen. Experimental Alprenolol Meclofenamic acid may decrease the antihypertensive activities of Alprenolol. Approved, Withdrawn Alprostadil The therapeutic efficacy of Alprostadil can be decreased when used in combination with Meclofenamic acid. Approved, Investigational Amcinonide The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Amcinonide. Approved Amikacin Meclofenamic acid may decrease the excretion rate of Amikacin which could result in a higher serum level. Approved, Investigational, Vet Approved Amiloride Meclofenamic acid may decrease the antihypertensive activities of Amiloride. Approved Amrubicin Meclofenamic acid may decrease the excretion rate of Amrubicin which could result in a higher serum level. Approved, Investigational Ancrod Meclofenamic acid may increase the anticoagulant activities of Ancrod. Approved, Investigational Andrographolide The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Andrographolide. Investigational Androstenedione The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Androstenedione. Experimental, Illicit Anecortave The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Anecortave. Investigational anecortave acetate The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with anecortave acetate. Investigational Anisodamine The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Anisodamine. Investigational Annamycin Meclofenamic acid may decrease the excretion rate of Annamycin which could result in a higher serum level. Investigational Antipyrine The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Antipyrine. Approved, Investigational Antithrombin III human Meclofenamic acid may increase the anticoagulant activities of Antithrombin III human. Approved Apixaban Meclofenamic acid may increase the anticoagulant activities of Apixaban. Approved Apocynin The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Apocynin. Investigational Apramycin Meclofenamic acid may decrease the excretion rate of Apramycin which could result in a higher serum level. Experimental, Vet Approved Apremilast The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Apremilast. Approved, Investigational Arbekacin Meclofenamic acid may decrease the excretion rate of Arbekacin which could result in a higher serum level. Approved, Investigational Ardeparin Meclofenamic acid may increase the anticoagulant activities of Ardeparin. Approved, Investigational, Withdrawn Argatroban Meclofenamic acid may increase the anticoagulant activities of Argatroban. Approved, Investigational Arotinolol Meclofenamic acid may decrease the antihypertensive activities of Arotinolol. Investigational Atamestane The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Atamestane. Investigational Atenolol Meclofenamic acid may decrease the antihypertensive activities of Atenolol. Approved Azapropazone The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Azapropazone. Withdrawn Azelastine The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Azelastine. Approved Azficel-T The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Azficel-T. Approved, Investigational Azilsartan medoxomil The risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Meclofenamic acid. Approved, Investigational Azosemide The therapeutic efficacy of Azosemide can be decreased when used in combination with Meclofenamic acid. Investigational Balsalazide Meclofenamic acid may increase the nephrotoxic activities of Balsalazide. Approved, Investigational Becaplermin Meclofenamic acid may increase the anticoagulant activities of Becaplermin. Approved, Investigational Beclomethasone dipropionate The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Beclomethasone dipropionate. Approved, Investigational Befunolol Meclofenamic acid may decrease the antihypertensive activities of Befunolol. Experimental Bekanamycin Meclofenamic acid may decrease the excretion rate of Bekanamycin which could result in a higher serum level. Experimental Benazepril The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Benazepril. Approved, Investigational Bendazac The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Bendazac. Experimental Bendroflumethiazide The therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Meclofenamic acid. Approved Benorilate The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Benorilate. Experimental Benoxaprofen The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Benoxaprofen. Withdrawn Benzydamine The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Benzydamine. Approved Beraprost The therapeutic efficacy of Beraprost can be decreased when used in combination with Meclofenamic acid. Investigational Betamethasone The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Betamethasone. Approved, Vet Approved Betaxolol Meclofenamic acid may decrease the antihypertensive activities of Betaxolol. Approved, Investigational Betrixaban The risk or severity of bleeding can be increased when Betrixaban is combined with Meclofenamic acid. Approved, Investigational Bevantolol Meclofenamic acid may decrease the antihypertensive activities of Bevantolol. Approved Bevonium The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Bevonium. Experimental Bimatoprost The therapeutic efficacy of Bimatoprost can be decreased when used in combination with Meclofenamic acid. Approved, Investigational Bisoprolol Meclofenamic acid may decrease the antihypertensive activities of Bisoprolol. Approved Bivalirudin Meclofenamic acid may increase the anticoagulant activities of Bivalirudin. Approved, Investigational Bopindolol Meclofenamic acid may decrease the antihypertensive activities of Bopindolol. Approved Bromfenac The risk or severity of adverse effects can be increased when Bromfenac is combined with Meclofenamic acid. Approved Bucillamine The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Bucillamine. Investigational Bucindolol Meclofenamic acid may decrease the antihypertensive activities of Bucindolol. Investigational Budesonide The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Budesonide. Approved Bufexamac The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Bufexamac. Approved, Experimental Bufuralol Meclofenamic acid may decrease the antihypertensive activities of Bufuralol. Experimental, Investigational Bumadizone The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Bumadizone. Experimental Bumetanide The therapeutic efficacy of Bumetanide can be decreased when used in combination with Meclofenamic acid. Approved Bupranolol Meclofenamic acid may decrease the antihypertensive activities of Bupranolol. Approved Candesartan The risk or severity of adverse effects can be increased when Candesartan is combined with Meclofenamic acid. Experimental Candesartan cilexetil The risk or severity of adverse effects can be increased when Candesartan cilexetil is combined with Meclofenamic acid. Approved Candoxatril The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Candoxatril. Experimental Captopril The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Captopril. Approved Carbaspirin calcium The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Carbaspirin calcium. Experimental, Investigational Carboprost Tromethamine The therapeutic efficacy of Carboprost Tromethamine can be decreased when used in combination with Meclofenamic acid. Approved Carprofen The risk or severity of adverse effects can be increased when Carprofen is combined with Meclofenamic acid. Approved, Vet Approved, Withdrawn Carteolol Meclofenamic acid may decrease the antihypertensive activities of Carteolol. Approved Carvedilol Meclofenamic acid may decrease the antihypertensive activities of Carvedilol. Approved, Investigational Castanospermine The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Castanospermine. Experimental Celecoxib The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Celecoxib. Approved, Investigational Celiprolol Meclofenamic acid may decrease the antihypertensive activities of Celiprolol. Approved, Investigational Certoparin Meclofenamic acid may increase the anticoagulant activities of Certoparin. Approved, Investigational Chloroquine The risk or severity of adverse effects can be increased when Chloroquine is combined with Meclofenamic acid. Approved, Investigational, Vet Approved Chlorothiazide The therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Meclofenamic acid. Approved, Vet Approved Chlorthalidone The therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Meclofenamic acid. Approved Cholestyramine Cholestyramine can cause a decrease in the absorption of Meclofenamic acid resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved, Investigational Choline magnesium trisalicylate The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Choline magnesium trisalicylate. Approved Ciclesonide The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Ciclesonide. Approved, Investigational Cilazapril The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Cilazapril. Approved Cinoxacin Meclofenamic acid may increase the neuroexcitatory activities of Cinoxacin. Approved, Investigational, Withdrawn Citric Acid Meclofenamic acid may increase the anticoagulant activities of Citric Acid. Approved, Nutraceutical, Vet Approved Clobetasol The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Clobetasol. Approved, Investigational Clobetasol propionate The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Clobetasol propionate. Approved Clobetasone The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Clobetasone. Approved Clocortolone The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Clocortolone. Approved Clodronic Acid The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Clodronic Acid. Approved, Investigational, Vet Approved Clonixin The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Clonixin. Approved Cloprostenol The therapeutic efficacy of Cloprostenol can be decreased when used in combination with Meclofenamic acid. Vet Approved Cloranolol Meclofenamic acid may decrease the antihypertensive activities of Cloranolol. Experimental Colesevelam Colesevelam can cause a decrease in the absorption of Meclofenamic acid resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved Colestipol Colestipol can cause a decrease in the absorption of Meclofenamic acid resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved Cortexolone 17α-propionate The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Cortexolone 17α-propionate. Investigational Corticosterone The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Corticosterone. Experimental Cortisone acetate The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Cortisone acetate. Approved, Investigational Curcumin The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Curcumin. Approved, Investigational Cyclopenthiazide The therapeutic efficacy of Cyclopenthiazide can be decreased when used in combination with Meclofenamic acid. Experimental Cyclosporine Meclofenamic acid may increase the nephrotoxic activities of Cyclosporine. Approved, Investigational, Vet Approved Dabigatran etexilate Meclofenamic acid may increase the anticoagulant activities of Dabigatran etexilate. Approved Dalteparin Meclofenamic acid may increase the anticoagulant activities of Dalteparin. Approved Danaparoid Meclofenamic acid may increase the anticoagulant activities of Danaparoid. Approved, Withdrawn Darexaban Meclofenamic acid may increase the anticoagulant activities of Darexaban. Investigational Daunorubicin Meclofenamic acid may decrease the excretion rate of Daunorubicin which could result in a higher serum level. Approved Deferasirox The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Deferasirox. Approved, Investigational Deflazacort The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Deflazacort. Approved, Investigational Delapril The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Delapril. Experimental Desirudin Meclofenamic acid may increase the anticoagulant activities of Desirudin. Approved Desmopressin The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Desmopressin. Approved Desonide The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Desonide. Approved, Investigational Desoximetasone The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Desoximetasone. Approved Desoxycorticosterone acetate The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Desoxycorticosterone acetate. Approved Desoxycorticosterone Pivalate The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Desoxycorticosterone Pivalate. Experimental, Vet Approved Dexamethasone The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Dexamethasone. Approved, Investigational, Vet Approved Dexamethasone isonicotinate The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Dexamethasone isonicotinate. Vet Approved Dexketoprofen The risk or severity of adverse effects can be increased when Dexketoprofen is combined with Meclofenamic acid. Approved, Investigational Dextran Meclofenamic acid may increase the anticoagulant activities of Dextran. Approved, Investigational, Vet Approved Dextran 40 Meclofenamic acid may increase the anticoagulant activities of Dextran 40. Approved Dextran 70 Meclofenamic acid may increase the anticoagulant activities of Dextran 70. Approved Dextran 75 Meclofenamic acid may increase the anticoagulant activities of Dextran 75. Approved Dibekacin Meclofenamic acid may decrease the excretion rate of Dibekacin which could result in a higher serum level. Experimental Dibotermin alfa The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Dibotermin alfa. Approved, Investigational Diclofenac The risk or severity of adverse effects can be increased when Diclofenac is combined with Meclofenamic acid. Approved, Vet Approved Dicoumarol Meclofenamic acid may increase the anticoagulant activities of Dicoumarol. Approved Difenpiramide The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Difenpiramide. Experimental Diflorasone The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Diflorasone. Approved Diflunisal The risk or severity of adverse effects can be increased when Diflunisal is combined with Meclofenamic acid. Approved, Investigational Difluocortolone The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Difluocortolone. Approved, Investigational, Withdrawn Difluprednate The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Difluprednate. Approved Digoxin The serum concentration of Digoxin can be increased when it is combined with Meclofenamic acid. Approved Dihydrostreptomycin Meclofenamic acid may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level. Investigational, Vet Approved Dinoprost The therapeutic efficacy of Dinoprost can be decreased when used in combination with Meclofenamic acid. Investigational Dinoprost Tromethamine The therapeutic efficacy of Dinoprost Tromethamine can be decreased when used in combination with Meclofenamic acid. Approved, Vet Approved Dinoprostone The therapeutic efficacy of Dinoprostone can be decreased when used in combination with Meclofenamic acid. Approved Doxorubicin Meclofenamic acid may decrease the excretion rate of Doxorubicin which could result in a higher serum level. Approved, Investigational Drospirenone Meclofenamic acid may increase the hyperkalemic activities of Drospirenone. Approved Droxicam The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Droxicam. Withdrawn Duvelisib The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Duvelisib. Investigational E-6201 The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with E-6201. Investigational Edetic Acid Meclofenamic acid may increase the anticoagulant activities of Edetic Acid. Approved, Vet Approved Edoxaban Meclofenamic acid may increase the anticoagulant activities of Edoxaban. Approved Enalapril The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Enalapril. Approved, Vet Approved Enalaprilat The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Enalaprilat. Approved Enoxacin Meclofenamic acid may increase the neuroexcitatory activities of Enoxacin. Approved, Investigational Enoxaparin Meclofenamic acid may increase the anticoagulant activities of Enoxaparin. Approved Enprostil The therapeutic efficacy of Enprostil can be decreased when used in combination with Meclofenamic acid. Experimental Epanolol Meclofenamic acid may decrease the antihypertensive activities of Epanolol. Experimental Epirizole The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Epirizole. Approved Epirubicin Meclofenamic acid may decrease the excretion rate of Epirubicin which could result in a higher serum level. Approved Epitizide The therapeutic efficacy of Epitizide can be decreased when used in combination with Meclofenamic acid. Experimental Eplerenone Meclofenamic acid may decrease the antihypertensive activities of Eplerenone. Approved Epoprostenol The therapeutic efficacy of Epoprostenol can be decreased when used in combination with Meclofenamic acid. Approved Eprosartan The risk or severity of adverse effects can be increased when Eprosartan is combined with Meclofenamic acid. Approved Equilenin The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Equilenin. Experimental Equilin The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Equilin. Approved Esmolol Meclofenamic acid may decrease the antihypertensive activities of Esmolol. Approved Estrone The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Estrone. Approved Estrone sulfate The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Estrone sulfate. Approved Etacrynic acid The therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Meclofenamic acid. Approved, Investigational Etanercept The risk or severity of adverse effects can be increased when Etanercept is combined with Meclofenamic acid. Approved, Investigational Ethenzamide The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Ethenzamide. Experimental Ethyl biscoumacetate Meclofenamic acid may increase the anticoagulant activities of Ethyl biscoumacetate. Withdrawn Etidronic acid The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Etidronic acid. Approved Etodolac The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Etodolac. Approved, Investigational, Vet Approved Etofenamate The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Etofenamate. Approved, Investigational Etoricoxib The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Etoricoxib. Approved, Investigational Evening primrose oil The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Evening primrose oil. Approved, Investigational Exisulind The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Exisulind. Investigational Felbinac The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Felbinac. Experimental Fenbufen The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Fenbufen. Approved Fenoprofen The risk or severity of adverse effects can be increased when Fenoprofen is combined with Meclofenamic acid. Approved Fenprostalene The therapeutic efficacy of Fenprostalene can be decreased when used in combination with Meclofenamic acid. Vet Approved Fentiazac The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Fentiazac. Experimental Feprazone The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Feprazone. Experimental Ferulic acid Meclofenamic acid may increase the anticoagulant activities of Ferulic acid. Experimental Fimasartan The risk or severity of adverse effects can be increased when Fimasartan is combined with Meclofenamic acid. Approved, Investigational Fleroxacin Meclofenamic acid may increase the neuroexcitatory activities of Fleroxacin. Approved Floctafenine The risk or severity of adverse effects can be increased when Floctafenine is combined with Meclofenamic acid. Approved, Withdrawn Fluasterone The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Fluasterone. Investigational Fludrocortisone The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Fludrocortisone. Approved, Investigational Fluindione Meclofenamic acid may increase the anticoagulant activities of Fluindione. Approved, Investigational Flumequine Meclofenamic acid may increase the neuroexcitatory activities of Flumequine. Withdrawn Flumethasone The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Flumethasone. Approved, Vet Approved Flunisolide The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Flunisolide. Approved, Investigational Flunixin The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Flunixin. Vet Approved Flunoxaprofen The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Flunoxaprofen. Experimental Fluocinolone Acetonide The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Fluocinolone Acetonide. Approved, Investigational, Vet Approved Fluocinonide The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Fluocinonide. Approved, Investigational Fluocortolone The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Fluocortolone. Approved, Withdrawn Fluorometholone The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Fluorometholone. Approved, Investigational Fluprednidene The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Fluprednidene. Approved, Withdrawn Fluprednisolone The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Fluprednisolone. Approved Fluprostenol The therapeutic efficacy of Fluprostenol can be decreased when used in combination with Meclofenamic acid. Vet Approved Flurandrenolide The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Flurandrenolide. Approved Flurbiprofen The risk or severity of adverse effects can be increased when Flurbiprofen is combined with Meclofenamic acid. Approved, Investigational Fluticasone furoate The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Fluticasone furoate. Approved Fluticasone propionate The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Fluticasone propionate. Approved Folic Acid The therapeutic efficacy of Folic Acid can be decreased when used in combination with Meclofenamic acid. Approved, Nutraceutical, Vet Approved Fondaparinux Meclofenamic acid may increase the anticoagulant activities of Fondaparinux. Approved, Investigational Fondaparinux sodium Meclofenamic acid may increase the anticoagulant activities of Fondaparinux sodium. Approved, Investigational Forasartan The risk or severity of adverse effects can be increased when Forasartan is combined with Meclofenamic acid. Experimental Formestane The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Formestane. Approved, Investigational, Withdrawn Fosinopril The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Fosinopril. Approved Framycetin Meclofenamic acid may decrease the excretion rate of Framycetin which could result in a higher serum level. Approved Furosemide The therapeutic efficacy of Furosemide can be decreased when used in combination with Meclofenamic acid. Approved, Vet Approved Gabexate Meclofenamic acid may increase the anticoagulant activities of Gabexate. Investigational Garenoxacin Meclofenamic acid may increase the neuroexcitatory activities of Garenoxacin. Investigational Gatifloxacin Meclofenamic acid may increase the neuroexcitatory activities of Gatifloxacin. Approved, Investigational Gemeprost The therapeutic efficacy of Gemeprost can be decreased when used in combination with Meclofenamic acid. Approved, Withdrawn Gemifloxacin Meclofenamic acid may increase the neuroexcitatory activities of Gemifloxacin. Approved, Investigational Geneticin Meclofenamic acid may decrease the excretion rate of Geneticin which could result in a higher serum level. Experimental Gentamicin Meclofenamic acid may decrease the excretion rate of Gentamicin which could result in a higher serum level. Approved, Vet Approved GENTAMICIN C1A Meclofenamic acid may decrease the excretion rate of GENTAMICIN C1A which could result in a higher serum level. Experimental GPX-150 Meclofenamic acid may decrease the excretion rate of GPX-150 which could result in a higher serum level. Investigational Grepafloxacin Meclofenamic acid may increase the neuroexcitatory activities of Grepafloxacin. Approved, Investigational, Withdrawn Guacetisal The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Guacetisal. Experimental Halcinonide The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Halcinonide. Approved, Investigational, Withdrawn Haloperidol The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Haloperidol. Approved HE3286 The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with HE3286. Investigational Heparin Meclofenamic acid may increase the anticoagulant activities of Heparin. Approved, Investigational Higenamine The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Higenamine. Investigational Hydralazine Meclofenamic acid may decrease the antihypertensive activities of Hydralazine. Approved Hydrochlorothiazide The therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Meclofenamic acid. Approved, Vet Approved Hydrocortisone The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Hydrocortisone. Approved, Vet Approved Hydroflumethiazide The therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Meclofenamic acid. Approved, Investigational Hygromycin B Meclofenamic acid may decrease the excretion rate of Hygromycin B which could result in a higher serum level. Vet Approved Ibandronate The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Ibandronate. Approved, Investigational Ibuprofen The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Ibuprofen. Approved Ibuproxam The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Ibuproxam. Withdrawn Icatibant The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Icatibant. Approved, Investigational Idarubicin Meclofenamic acid may decrease the excretion rate of Idarubicin which could result in a higher serum level. Approved Idraparinux Meclofenamic acid may increase the anticoagulant activities of Idraparinux. Investigational Iloprost The therapeutic efficacy of Iloprost can be decreased when used in combination with Meclofenamic acid. Approved, Investigational Imidapril The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Imidapril. Investigational Imidazole salicylate The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Imidazole salicylate. Experimental Indapamide The therapeutic efficacy of Indapamide can be decreased when used in combination with Meclofenamic acid. Approved Indenolol Meclofenamic acid may decrease the antihypertensive activities of Indenolol. Withdrawn Indobufen The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Indobufen. Investigational Indomethacin The risk or severity of adverse effects can be increased when Indomethacin is combined with Meclofenamic acid. Approved, Investigational Indoprofen The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Indoprofen. Withdrawn Irbesartan The risk or severity of adverse effects can be increased when Irbesartan is combined with Meclofenamic acid. Approved, Investigational Isepamicin Meclofenamic acid may decrease the excretion rate of Isepamicin which could result in a higher serum level. Experimental Isoxicam The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Isoxicam. Withdrawn Istaroxime The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Istaroxime. Investigational Kanamycin Meclofenamic acid may decrease the excretion rate of Kanamycin which could result in a higher serum level. Approved, Investigational, Vet Approved Kebuzone The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Kebuzone. Experimental Ketoprofen The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Ketoprofen. Approved, Vet Approved Ketorolac The risk or severity of adverse effects can be increased when Ketorolac is combined with Meclofenamic acid. Approved Labetalol Meclofenamic acid may decrease the antihypertensive activities of Labetalol. Approved Landiolol Meclofenamic acid may decrease the antihypertensive activities of Landiolol. Investigational Latanoprost The therapeutic efficacy of Latanoprost can be decreased when used in combination with Meclofenamic acid. Approved, Investigational Latanoprostene Bunod The therapeutic efficacy of Latanoprostene Bunod can be decreased when used in combination with Meclofenamic acid. Approved, Investigational Leflunomide The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Leflunomide. Approved, Investigational Lepirudin Meclofenamic acid may increase the anticoagulant activities of Lepirudin. Approved Letaxaban Meclofenamic acid may increase the anticoagulant activities of Letaxaban. Investigational Levobunolol Meclofenamic acid may decrease the antihypertensive activities of Levobunolol. Approved Levofloxacin Meclofenamic acid may increase the neuroexcitatory activities of Levofloxacin. Approved, Investigational Limaprost The therapeutic efficacy of Limaprost can be decreased when used in combination with Meclofenamic acid. Approved, Investigational Lisinopril The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Lisinopril. Approved, Investigational Lisofylline The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Lisofylline. Investigational Lithium The serum concentration of Lithium can be increased when it is combined with Meclofenamic acid. Approved Lonazolac The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Lonazolac. Experimental Lornoxicam The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Lornoxicam. Approved, Investigational Losartan The risk or severity of adverse effects can be increased when Losartan is combined with Meclofenamic acid. Approved Loteprednol The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Loteprednol. Approved Loxoprofen The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Loxoprofen. Approved, Investigational Lubiprostone The therapeutic efficacy of Lubiprostone can be decreased when used in combination with Meclofenamic acid. Approved, Investigational Lumiracoxib The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Lumiracoxib. Approved, Investigational Luprostiol The therapeutic efficacy of Luprostiol can be decreased when used in combination with Meclofenamic acid. Vet Approved Magnesium salicylate The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Magnesium salicylate. Approved Masoprocol The risk or severity of adverse effects can be increased when Masoprocol is combined with Meclofenamic acid. Approved, Investigational ME-609 The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with ME-609. Investigational Medrysone The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Medrysone. Approved Mefenamic acid The risk or severity of adverse effects can be increased when Mefenamic acid is combined with Meclofenamic acid. Approved Melagatran Meclofenamic acid may increase the anticoagulant activities of Melagatran. Experimental Melengestrol The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Melengestrol. Vet Approved Meloxicam The risk or severity of adverse effects can be increased when Meloxicam is combined with Meclofenamic acid. Approved, Vet Approved Mepindolol Meclofenamic acid may decrease the antihypertensive activities of Mepindolol. Experimental Mesalazine Meclofenamic acid may increase the nephrotoxic activities of Mesalazine. Approved Metamizole The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Metamizole. Approved, Investigational, Withdrawn Methotrexate The serum concentration of Methotrexate can be increased when it is combined with Meclofenamic acid. Approved Methyclothiazide The therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Meclofenamic acid. Approved Methylprednisolone The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Methylprednisolone. Approved, Vet Approved Metipranolol Meclofenamic acid may decrease the antihypertensive activities of Metipranolol. Approved Metolazone The therapeutic efficacy of Metolazone can be decreased when used in combination with Meclofenamic acid. Approved Metoprolol Meclofenamic acid may decrease the antihypertensive activities of Metoprolol. Approved, Investigational Metrizamide Meclofenamic acid may decrease the excretion rate of Metrizamide which could result in a higher serum level. Approved Micronomicin Meclofenamic acid may decrease the excretion rate of Micronomicin which could result in a higher serum level. Experimental Mifamurtide The therapeutic efficacy of Mifamurtide can be decreased when used in combination with Meclofenamic acid. Approved, Experimental Misoprostol The therapeutic efficacy of Misoprostol can be decreased when used in combination with Meclofenamic acid. Approved Mizoribine The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Mizoribine. Investigational Moexipril The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Moexipril. Approved Mofebutazone The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Mofebutazone. Experimental Mometasone The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Mometasone. Approved, Vet Approved Morniflumate The risk or severity of adverse effects can be increased when Morniflumate is combined with Meclofenamic acid. Approved Mycophenolate mofetil The risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Meclofenamic acid. Approved, Investigational Mycophenolic acid The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Mycophenolic acid. Approved Nabumetone The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Nabumetone. Approved Nadolol Meclofenamic acid may decrease the antihypertensive activities of Nadolol. Approved Nadroparin Meclofenamic acid may increase the anticoagulant activities of Nadroparin. Approved, Investigational Nafamostat Meclofenamic acid may increase the anticoagulant activities of Nafamostat. Approved, Investigational Naftifine The risk or severity of adverse effects can be increased when Naftifine is combined with Meclofenamic acid. Approved Nalidixic Acid Meclofenamic acid may increase the neuroexcitatory activities of Nalidixic Acid. Approved, Investigational Naproxen The risk or severity of adverse effects can be increased when Naproxen is combined with Meclofenamic acid. Approved, Vet Approved NCX 1022 The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with NCX 1022. Investigational Neamine Meclofenamic acid may decrease the excretion rate of Neamine which could result in a higher serum level. Experimental Nebivolol Meclofenamic acid may decrease the antihypertensive activities of Nebivolol. Approved, Investigational Nemonoxacin Meclofenamic acid may increase the neuroexcitatory activities of Nemonoxacin. Investigational Neomycin Meclofenamic acid may decrease the excretion rate of Neomycin which could result in a higher serum level. Approved, Vet Approved Nepafenac The risk or severity of adverse effects can be increased when Nepafenac is combined with Meclofenamic acid. Approved, Investigational Netilmicin Meclofenamic acid may decrease the excretion rate of Netilmicin which could result in a higher serum level. Approved, Investigational Nifenazone The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Nifenazone. Experimental Niflumic Acid The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Niflumic Acid. Approved Nimesulide The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Nimesulide. Approved, Investigational, Withdrawn Nitroaspirin The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Nitroaspirin. Investigational Norfloxacin Meclofenamic acid may increase the neuroexcitatory activities of Norfloxacin. Approved Oleoyl-estrone The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Oleoyl-estrone. Investigational Olmesartan The risk or severity of adverse effects can be increased when Olmesartan is combined with Meclofenamic acid. Approved, Investigational Olopatadine The risk or severity of adverse effects can be increased when Olopatadine is combined with Meclofenamic acid. Approved Olsalazine Meclofenamic acid may increase the nephrotoxic activities of Olsalazine. Approved Omacetaxine mepesuccinate The risk or severity of bleeding can be increased when Meclofenamic acid is combined with Omacetaxine mepesuccinate. Approved, Investigational Omapatrilat The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Omapatrilat. Investigational Orgotein The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Orgotein. Vet Approved Otamixaban Meclofenamic acid may increase the anticoagulant activities of Otamixaban. Investigational Oxaprozin The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Oxaprozin. Approved Oxolinic acid Meclofenamic acid may increase the neuroexcitatory activities of Oxolinic acid. Experimental Oxprenolol Meclofenamic acid may decrease the antihypertensive activities of Oxprenolol. Approved Oxyphenbutazone The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Oxyphenbutazone. Approved, Withdrawn Pamidronate The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Pamidronate. Approved Paramethasone The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Paramethasone. Approved Parecoxib The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Parecoxib. Approved Paromomycin Meclofenamic acid may decrease the excretion rate of Paromomycin which could result in a higher serum level. Approved, Investigational Parthenolide The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Parthenolide. Approved, Investigational Pazufloxacin Meclofenamic acid may increase the neuroexcitatory activities of Pazufloxacin. Investigational Pefloxacin Meclofenamic acid may increase the neuroexcitatory activities of Pefloxacin. Approved Penbutolol Meclofenamic acid may decrease the antihypertensive activities of Penbutolol. Approved, Investigational Pentaerythritol Tetranitrate Meclofenamic acid may increase the anticoagulant activities of Pentaerythritol Tetranitrate. Approved Pentosan Polysulfate Meclofenamic acid may increase the anticoagulant activities of Pentosan Polysulfate. Approved Perindopril The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Perindopril. Approved Phenindione Meclofenamic acid may increase the anticoagulant activities of Phenindione. Approved, Investigational Phenprocoumon Meclofenamic acid may increase the anticoagulant activities of Phenprocoumon. Approved, Investigational Phenylbutazone The risk or severity of adverse effects can be increased when Phenylbutazone is combined with Meclofenamic acid. Approved, Vet Approved Pimecrolimus The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Meclofenamic acid. Approved, Investigational Pindolol Meclofenamic acid may decrease the antihypertensive activities of Pindolol. Approved, Investigational Pipemidic acid Meclofenamic acid may increase the neuroexcitatory activities of Pipemidic acid. Experimental Pirarubicin Meclofenamic acid may decrease the excretion rate of Pirarubicin which could result in a higher serum level. Investigational Piretanide The therapeutic efficacy of Piretanide can be decreased when used in combination with Meclofenamic acid. Approved Pirfenidone The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Pirfenidone. Approved, Investigational Piromidic acid Meclofenamic acid may increase the neuroexcitatory activities of Piromidic acid. Experimental Piroxicam The risk or severity of adverse effects can be increased when Piroxicam is combined with Meclofenamic acid. Approved, Investigational Pirprofen The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Pirprofen. Experimental Pitolisant The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Pitolisant. Approved, Investigational Platelet Activating Factor Meclofenamic acid may decrease the antihypertensive activities of Platelet Activating Factor. Experimental Plazomicin Meclofenamic acid may decrease the excretion rate of Plazomicin which could result in a higher serum level. Investigational Plicamycin Meclofenamic acid may decrease the excretion rate of Plicamycin which could result in a higher serum level. Approved, Investigational, Withdrawn Polythiazide The therapeutic efficacy of Polythiazide can be decreased when used in combination with Meclofenamic acid. Approved Practolol Meclofenamic acid may decrease the antihypertensive activities of Practolol. Approved Pralatrexate The serum concentration of Pralatrexate can be increased when it is combined with Meclofenamic acid. Approved, Investigational Pranoprofen The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Pranoprofen. Experimental, Investigational Prasterone The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Prasterone. Approved, Investigational, Nutraceutical Prasterone sulfate The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Prasterone sulfate. Investigational Prednicarbate The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Prednicarbate. Approved, Investigational Prednisolone The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Prednisolone. Approved, Vet Approved Prednisone The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Prednisone. Approved, Vet Approved Pregnenolone The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Pregnenolone. Approved, Experimental, Investigational Probenecid The serum concentration of Meclofenamic acid can be increased when it is combined with Probenecid. Approved, Investigational Proglumetacin The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Proglumetacin. Experimental Propacetamol The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Propacetamol. Approved, Investigational Propranolol Meclofenamic acid may decrease the antihypertensive activities of Propranolol. Approved, Investigational Propyphenazone The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Propyphenazone. Experimental Proquazone The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Proquazone. Experimental Prostaglandin B2 The therapeutic efficacy of Prostaglandin B2 can be decreased when used in combination with Meclofenamic acid. Experimental Prostaglandin G2 The therapeutic efficacy of Prostaglandin G2 can be decreased when used in combination with Meclofenamic acid. Experimental Prostalene The therapeutic efficacy of Prostalene can be decreased when used in combination with Meclofenamic acid. Vet Approved Protein C Meclofenamic acid may increase the anticoagulant activities of Protein C. Approved Protein S human Meclofenamic acid may increase the anticoagulant activities of Protein S human. Approved Protocatechualdehyde Meclofenamic acid may increase the anticoagulant activities of Protocatechualdehyde. Approved Prulifloxacin Meclofenamic acid may increase the neuroexcitatory activities of Prulifloxacin. Investigational PTC299 The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with PTC299. Investigational Puromycin Meclofenamic acid may decrease the excretion rate of Puromycin which could result in a higher serum level. Experimental Quinapril The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Quinapril. Approved, Investigational Quinethazone The therapeutic efficacy of Quinethazone can be decreased when used in combination with Meclofenamic acid. Approved Ramipril The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Ramipril. Approved Rescinnamine The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Rescinnamine. Approved Resveratrol The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Resveratrol. Approved, Experimental, Investigational Reviparin Meclofenamic acid may increase the anticoagulant activities of Reviparin. Approved, Investigational Ribostamycin Meclofenamic acid may decrease the excretion rate of Ribostamycin which could result in a higher serum level. Approved, Investigational Rimexolone The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Rimexolone. Approved Risedronate The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Risedronate. Approved, Investigational Rivaroxaban Meclofenamic acid may increase the anticoagulant activities of Rivaroxaban. Approved Rofecoxib The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Rofecoxib. Approved, Investigational, Withdrawn Rosoxacin Meclofenamic acid may increase the neuroexcitatory activities of Rosoxacin. Approved, Investigational Rufloxacin Meclofenamic acid may increase the neuroexcitatory activities of Rufloxacin. Experimental Sabarubicin Meclofenamic acid may decrease the excretion rate of Sabarubicin which could result in a higher serum level. Investigational Sacubitril The risk or severity of adverse effects can be increased when Sacubitril is combined with Meclofenamic acid. Approved Salicylamide The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Salicylamide. Approved Salicylic acid The risk or severity of adverse effects can be increased when Salicylic acid is combined with Meclofenamic acid. Approved, Investigational, Vet Approved Salsalate The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Salsalate. Approved Saprisartan The risk or severity of adverse effects can be increased when Saprisartan is combined with Meclofenamic acid. Experimental Saralasin The risk or severity of adverse effects can be increased when Saralasin is combined with Meclofenamic acid. Investigational Sarilumab Sarilumab may increase the immunosuppressive activities of Meclofenamic acid. Approved, Investigational Semapimod The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Semapimod. Investigational Seratrodast The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Seratrodast. Approved Serrapeptase The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Serrapeptase. Investigational Sisomicin Meclofenamic acid may decrease the excretion rate of Sisomicin which could result in a higher serum level. Investigational Sitafloxacin Meclofenamic acid may increase the neuroexcitatory activities of Sitafloxacin. Experimental, Investigational Sodium phosphate Sodium phosphate may increase the nephrotoxic activities of Meclofenamic acid. Approved Sotalol Meclofenamic acid may decrease the antihypertensive activities of Sotalol. Approved SP1049C Meclofenamic acid may decrease the excretion rate of SP1049C which could result in a higher serum level. Investigational Sparfloxacin Meclofenamic acid may increase the neuroexcitatory activities of Sparfloxacin. Approved, Investigational Spectinomycin Meclofenamic acid may decrease the excretion rate of Spectinomycin which could result in a higher serum level. Approved, Investigational, Vet Approved Spirapril The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Spirapril. Approved Spironolactone Meclofenamic acid may decrease the antihypertensive activities of Spironolactone. Approved SRT501 The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with SRT501. Investigational Streptomycin Meclofenamic acid may decrease the excretion rate of Streptomycin which could result in a higher serum level. Approved, Vet Approved Streptozocin Meclofenamic acid may decrease the excretion rate of Streptozocin which could result in a higher serum level. Approved, Investigational Sulfasalazine The risk or severity of adverse effects can be increased when Sulfasalazine is combined with Meclofenamic acid. Approved Sulindac The risk or severity of adverse effects can be increased when Sulindac is combined with Meclofenamic acid. Approved, Investigational Sulodexide Meclofenamic acid may increase the anticoagulant activities of Sulodexide. Approved, Investigational Sulprostone The therapeutic efficacy of Sulprostone can be decreased when used in combination with Meclofenamic acid. Investigational Suprofen The risk or severity of adverse effects can be increased when Suprofen is combined with Meclofenamic acid. Approved, Withdrawn Suxibuzone The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Suxibuzone. Experimental Tacrolimus Meclofenamic acid may increase the nephrotoxic activities of Tacrolimus. Approved, Investigational Tafluprost The therapeutic efficacy of Tafluprost can be decreased when used in combination with Meclofenamic acid. Approved Talinolol Meclofenamic acid may decrease the antihypertensive activities of Talinolol. Investigational Talniflumate The risk or severity of adverse effects can be increased when Talniflumate is combined with Meclofenamic acid. Approved Tarenflurbil The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Tarenflurbil. Investigational Tasosartan The risk or severity of adverse effects can be increased when Tasosartan is combined with Meclofenamic acid. Approved Technetium Tc-99m etidronate The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Technetium Tc-99m etidronate. Approved Technetium Tc-99m medronate The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Technetium Tc-99m medronate. Approved Telmisartan The risk or severity of adverse effects can be increased when Telmisartan is combined with Meclofenamic acid. Approved, Investigational Temafloxacin Meclofenamic acid may increase the neuroexcitatory activities of Temafloxacin. Withdrawn Temocapril The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Temocapril. Experimental, Investigational Tenidap The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Tenidap. Experimental Tenofovir disoproxil The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Tenofovir disoproxil. Approved, Investigational Tenoxicam The risk or severity of adverse effects can be increased when Tenoxicam is combined with Meclofenamic acid. Approved Tepoxalin The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Tepoxalin. Vet Approved Teriflunomide The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Teriflunomide. Approved Tertatolol Meclofenamic acid may decrease the antihypertensive activities of Tertatolol. Experimental Tiaprofenic acid The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Tiaprofenic acid. Approved Tiludronic acid The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Tiludronic acid. Approved, Investigational, Vet Approved Timolol Meclofenamic acid may decrease the antihypertensive activities of Timolol. Approved Tinoridine The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Tinoridine. Investigational Tixocortol The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Tixocortol. Approved, Withdrawn Tobramycin Meclofenamic acid may decrease the excretion rate of Tobramycin which could result in a higher serum level. Approved, Investigational Tolfenamic Acid The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Tolfenamic Acid. Approved, Investigational Tolmetin The risk or severity of adverse effects can be increased when Tolmetin is combined with Meclofenamic acid. Approved Torasemide The therapeutic efficacy of Torasemide can be decreased when used in combination with Meclofenamic acid. Approved Trandolapril The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Trandolapril. Approved Tranilast The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Tranilast. Approved, Investigational Travoprost The therapeutic efficacy of Travoprost can be decreased when used in combination with Meclofenamic acid. Approved Treprostinil The risk or severity of adverse effects can be increased when Treprostinil is combined with Meclofenamic acid. Approved, Investigational Triamcinolone The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Triamcinolone. Approved, Vet Approved Triamterene Meclofenamic acid may decrease the antihypertensive activities of Triamterene. Approved Tribenoside The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Tribenoside. Experimental Trichlormethiazide The therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Meclofenamic acid. Approved, Vet Approved Triptolide The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Triptolide. Investigational Trovafloxacin Meclofenamic acid may increase the neuroexcitatory activities of Trovafloxacin. Approved, Investigational, Withdrawn Troxerutin Meclofenamic acid may increase the anticoagulant activities of Troxerutin. Investigational Ulobetasol The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Ulobetasol. Approved Unoprostone The therapeutic efficacy of Unoprostone can be decreased when used in combination with Meclofenamic acid. Approved, Investigational Valdecoxib The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Valdecoxib. Approved, Investigational, Withdrawn Valrubicin Meclofenamic acid may decrease the excretion rate of Valrubicin which could result in a higher serum level. Approved Valsartan The risk or severity of adverse effects can be increased when Valsartan is combined with Meclofenamic acid. Approved, Investigational Vancomycin The serum concentration of Vancomycin can be increased when it is combined with Meclofenamic acid. Approved Warfarin Meclofenamic acid may increase the anticoagulant activities of Warfarin. Approved Ximelagatran Meclofenamic acid may increase the anticoagulant activities of Ximelagatran. Approved, Investigational, Withdrawn Zaltoprofen The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Zaltoprofen. Approved, Investigational Zileuton The risk or severity of adverse effects can be increased when Zileuton is combined with Meclofenamic acid. Approved, Investigational, Withdrawn Zofenopril The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Zofenopril. Experimental Zoledronic acid The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Zoledronic acid. Approved Zomepirac The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Zomepirac. Withdrawn Zoptarelin doxorubicin Meclofenamic acid may decrease the excretion rate of Zoptarelin doxorubicin which could result in a higher serum level. Investigational Zorubicin Meclofenamic acid may decrease the excretion rate of Zorubicin which could result in a higher serum level. Experimental - Food Interactions
- Not Available
References
- Synthesis Reference
U.S. Patent 3,313,848.
- General References
- Not Available
- External Links
- Human Metabolome Database
- HMDB0015074
- KEGG Drug
- D02341
- KEGG Compound
- C07117
- PubChem Compound
- 4037
- PubChem Substance
- 46507887
- ChemSpider
- 3897
- BindingDB
- 22971
- ChEBI
- 6710
- ChEMBL
- CHEMBL509
- Therapeutic Targets Database
- DNC000919
- PharmGKB
- PA450341
- HET
- JMS
- RxList
- RxList Drug Page
- Wikipedia
- Meclofenamic_acid
- ATC Codes
- M01AG04 — Meclofenamic acid
- M01AG — Fenamates
- M01A — ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS
- M01 — ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS
- M — MUSCULO-SKELETAL SYSTEM
- PDB Entries
- 3r6i / 4n6p / 4qkn / 5ikq
- MSDS
- Download (74.2 KB)
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 2 Enrolling by Invitation Treatment Bipolar Disorder (BD) / Psychotic Disorder NOS / Schizoaffective Disorders / Schizophrenic Disorders 1 Not Available Recruiting Treatment Progressive Brain Metastases / Recurrent Brain Metastases 1
Pharmacoeconomics
- Manufacturers
- Quantum pharmics ltd
- American therapeutics inc
- Barr laboratories inc
- Mylan pharmaceuticals inc
- Par pharmaceutical inc
- Sandoz inc
- Usl pharma inc
- Vitarine pharmaceuticals inc
- Watson laboratories inc
- Parke davis div warner lambert co
- Packagers
- Dispensing Solutions
- Mylan
- Nucare Pharmaceuticals Inc.
- Pharmedix
- Physicians Total Care Inc.
- Sandhills Packaging Inc.
- Dosage forms
Form Route Strength Capsule Oral 100 mg/1 Capsule Oral 50 mg/1 - Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Solid
- Experimental Properties
Property Value Source melting point (°C) 248-250 U.S. Patent 3,313,848. water solubility 30 mg/L MERCK INDEX (1996) logP 5 Not Available - Predicted Properties
Property Value Source Water Solubility 0.00366 mg/mL ALOGPS logP 5.11 ALOGPS logP 6.09 ChemAxon logS -4.9 ALOGPS pKa (Strongest Acidic) 3.79 ChemAxon pKa (Strongest Basic) -3.6 ChemAxon Physiological Charge -1 ChemAxon Hydrogen Acceptor Count 3 ChemAxon Hydrogen Donor Count 2 ChemAxon Polar Surface Area 49.33 Å2 ChemAxon Rotatable Bond Count 3 ChemAxon Refractivity 76.45 m3·mol-1 ChemAxon Polarizability 28.44 Å3 ChemAxon Number of Rings 2 ChemAxon Bioavailability 1 ChemAxon Rule of Five No ChemAxon Ghose Filter No ChemAxon Veber's Rule No ChemAxon MDDR-like Rule No ChemAxon - Predicted ADMET features
Property Value Probability Human Intestinal Absorption + 0.9393 Blood Brain Barrier + 0.8668 Caco-2 permeable + 0.8398 P-glycoprotein substrate Non-substrate 0.806 P-glycoprotein inhibitor I Non-inhibitor 0.8943 P-glycoprotein inhibitor II Non-inhibitor 0.9474 Renal organic cation transporter Non-inhibitor 0.9094 CYP450 2C9 substrate Non-substrate 0.6402 CYP450 2D6 substrate Non-substrate 0.9164 CYP450 3A4 substrate Non-substrate 0.6566 CYP450 1A2 substrate Inhibitor 0.9236 CYP450 2C9 inhibitor Inhibitor 0.9106 CYP450 2D6 inhibitor Non-inhibitor 0.923 CYP450 2C19 inhibitor Non-inhibitor 0.8271 CYP450 3A4 inhibitor Non-inhibitor 0.8308 CYP450 inhibitory promiscuity Low CYP Inhibitory Promiscuity 0.558 Ames test Non AMES toxic 0.8633 Carcinogenicity Non-carcinogens 0.5329 Biodegradation Not ready biodegradable 0.9709 Rat acute toxicity 3.0345 LD50, mol/kg Not applicable hERG inhibition (predictor I) Weak inhibitor 0.9502 hERG inhibition (predictor II) Non-inhibitor 0.872
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Taxonomy
- Description
- This compound belongs to the class of organic compounds known as aminobenzoic acids. These are benzoic acids containing an amine group attached to the benzene moiety.
- Kingdom
- Organic compounds
- Super Class
- Benzenoids
- Class
- Benzene and substituted derivatives
- Sub Class
- Benzoic acids and derivatives
- Direct Parent
- Aminobenzoic acids
- Alternative Parents
- Benzoic acids / Aminotoluenes / Aniline and substituted anilines / Dichlorobenzenes / Benzoyl derivatives / Aryl chlorides / Vinylogous amides / Amino acids / Secondary amines / Monocarboxylic acids and derivatives show 6 more
- Substituents
- Aminobenzoic acid / Benzoic acid / Benzoyl / 1,3-dichlorobenzene / Aniline or substituted anilines / Aminotoluene / Toluene / Chlorobenzene / Halobenzene / Aryl chloride show 19 more
- Molecular Framework
- Aromatic homomonocyclic compounds
- External Descriptors
- organochlorine compound, secondary amino compound, aminobenzoic acid (CHEBI:6710)
Targets
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Yes
- Actions
- Inhibitor
- General Function
- Prostaglandin-endoperoxide synthase activity
- Specific Function
- Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Involved in the constitutive production of prostanoids in particular in the stomach and platelets. In gas...
- Gene Name
- PTGS1
- Uniprot ID
- P23219
- Uniprot Name
- Prostaglandin G/H synthase 1
- Molecular Weight
- 68685.82 Da
References
- Perez-Vizcaino F, Lopez-Lopez JG, Santiago R, Cogolludo A, Zaragoza-Arnaez F, Moreno L, Alonso MJ, Salaices M, Tamargo J: Postnatal maturation in nitric oxide-induced pulmonary artery relaxation involving cyclooxygenase-1 activity. Am J Physiol Lung Cell Mol Physiol. 2002 Oct;283(4):L839-48. [PubMed:12225961]
- Shiels IA, Whitehouse MW: Lyprinol: anti-inflammatory and uterine-relaxant activities in rats, with special reference to a model for dysmenorrhoea. Allerg Immunol (Paris). 2000 Sep;32(7):279-83. [PubMed:11094641]
- Wilson JE, Chandrasekharan NV, Westover KD, Eager KB, Simmons DL: Determination of expression of cyclooxygenase-1 and -2 isozymes in canine tissues and their differential sensitivity to nonsteroidal anti-inflammatory drugs. Am J Vet Res. 2004 Jun;65(6):810-8. [PubMed:15198222]
- Kalgutkar AS, Crews BC, Rowlinson SW, Marnett AB, Kozak KR, Remmel RP, Marnett LJ: Biochemically based design of cyclooxygenase-2 (COX-2) inhibitors: facile conversion of nonsteroidal antiinflammatory drugs to potent and highly selective COX-2 inhibitors. Proc Natl Acad Sci U S A. 2000 Jan 18;97(2):925-30. [PubMed:10639181]
- Meade EA, Smith WL, DeWitt DL: Differential inhibition of prostaglandin endoperoxide synthase (cyclooxygenase) isozymes by aspirin and other non-steroidal anti-inflammatory drugs. J Biol Chem. 1993 Mar 25;268(9):6610-4. [PubMed:8454631]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Yes
- Actions
- Inhibitor
- General Function
- Prostaglandin-endoperoxide synthase activity
- Specific Function
- Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Constitutively expressed in some tissues in physiological conditions, such as the endothelium, kidney and...
- Gene Name
- PTGS2
- Uniprot ID
- P35354
- Uniprot Name
- Prostaglandin G/H synthase 2
- Molecular Weight
- 68995.625 Da
References
- Kalgutkar AS, Crews BC, Rowlinson SW, Marnett AB, Kozak KR, Remmel RP, Marnett LJ: Biochemically based design of cyclooxygenase-2 (COX-2) inhibitors: facile conversion of nonsteroidal antiinflammatory drugs to potent and highly selective COX-2 inhibitors. Proc Natl Acad Sci U S A. 2000 Jan 18;97(2):925-30. [PubMed:10639181]
- Traupe T, Lang M, Goettsch W, Munter K, Morawietz H, Vetter W, Barton M: Obesity increases prostanoid-mediated vasoconstriction and vascular thromboxane receptor gene expression. J Hypertens. 2002 Nov;20(11):2239-45. [PubMed:12409963]
- Wilson JE, Chandrasekharan NV, Westover KD, Eager KB, Simmons DL: Determination of expression of cyclooxygenase-1 and -2 isozymes in canine tissues and their differential sensitivity to nonsteroidal anti-inflammatory drugs. Am J Vet Res. 2004 Jun;65(6):810-8. [PubMed:15198222]
- Narsinghani T, Chaturvedi SC: QSAR analysis of meclofenamic acid analogues as selective COX-2 inhibitors. Bioorg Med Chem Lett. 2006 Jan 15;16(2):461-8. Epub 2005 Nov 14. [PubMed:16290292]
- Smith WL, Meade EA, DeWitt DL: Interactions of PGH synthase isozymes-1 and -2 with NSAIDs. Ann N Y Acad Sci. 1994 Nov 15;744:50-7. [PubMed:7825862]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Yes
- Actions
- Inhibitor
- General Function
- Iron ion binding
- Specific Function
- Catalyzes the first step in leukotriene biosynthesis, and thereby plays a role in inflammatory processes.
- Gene Name
- ALOX5
- Uniprot ID
- P09917
- Uniprot Name
- Arachidonate 5-lipoxygenase
- Molecular Weight
- 77982.595 Da
References
- Yu XY, Hubbard W, Spannhake EW: Inhibition of canine tracheal smooth muscle by mediators from cultured bronchial epithelial cells. Am J Physiol. 1992 Feb;262(2 Pt 1):L229-34. [PubMed:1539679]
- Boctor AM, Eickholt M, Pugsley TA: Meclofenamate sodium is an inhibitor of both the 5-lipoxygenase and cyclooxygenase pathways of the arachidonic acid cascade in vitro. Prostaglandins Leukot Med. 1986 Aug;23(2-3):229-38. [PubMed:3020588]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- Other
- General Function
- Voltage-gated potassium channel activity
- Specific Function
- Probably important in the regulation of neuronal excitability. Associates with KCNQ3 to form a potassium channel with essentially identical properties to the channel underlying the native M-current...
- Gene Name
- KCNQ2
- Uniprot ID
- O43526
- Uniprot Name
- Potassium voltage-gated channel subfamily KQT member 2
- Molecular Weight
- 95846.575 Da
References
- Peretz A, Degani N, Nachman R, Uziyel Y, Gibor G, Shabat D, Attali B: Meclofenamic acid and diclofenac, novel templates of KCNQ2/Q3 potassium channel openers, depress cortical neuron activity and exhibit anticonvulsant properties. Mol Pharmacol. 2005 Apr;67(4):1053-66. Epub 2004 Dec 14. [PubMed:15598972]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- Other
- General Function
- Voltage-gated potassium channel activity
- Specific Function
- Probably important in the regulation of neuronal excitability. Associates with KCNQ2 or KCNQ5 to form a potassium channel with essentially identical properties to the channel underlying the native ...
- Gene Name
- KCNQ3
- Uniprot ID
- O43525
- Uniprot Name
- Potassium voltage-gated channel subfamily KQT member 3
- Molecular Weight
- 96741.515 Da
References
- Peretz A, Degani N, Nachman R, Uziyel Y, Gibor G, Shabat D, Attali B: Meclofenamic acid and diclofenac, novel templates of KCNQ2/Q3 potassium channel openers, depress cortical neuron activity and exhibit anticonvulsant properties. Mol Pharmacol. 2005 Apr;67(4):1053-66. Epub 2004 Dec 14. [PubMed:15598972]
Transporters
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- Inhibitor
- General Function
- Sodium-independent organic anion transmembrane transporter activity
- Specific Function
- Involved in the renal elimination of endogenous and exogenous organic anions. Functions as organic anion exchanger when the uptake of one molecule of organic anion is coupled with an efflux of one ...
- Gene Name
- SLC22A6
- Uniprot ID
- Q4U2R8
- Uniprot Name
- Solute carrier family 22 member 6
- Molecular Weight
- 61815.78 Da
References
- Apiwattanakul N, Sekine T, Chairoungdua A, Kanai Y, Nakajima N, Sophasan S, Endou H: Transport properties of nonsteroidal anti-inflammatory drugs by organic anion transporter 1 expressed in Xenopus laevis oocytes. Mol Pharmacol. 1999 May;55(5):847-54. [PubMed:10220563]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- Inhibitor
- General Function
- Thyroid hormone transmembrane transporter activity
- Specific Function
- Mediates the Na(+)-independent high affinity transport of organic anions such as the thyroid hormones thyroxine (T4) and rT3. Other potential substrates, such as triiodothyronine (T3), 17-beta-gluc...
- Gene Name
- SLCO1C1
- Uniprot ID
- Q9NYB5
- Uniprot Name
- Solute carrier organic anion transporter family member 1C1
- Molecular Weight
- 78695.625 Da
References
- Westholm DE, Stenehjem DD, Rumbley JN, Drewes LR, Anderson GW: Competitive inhibition of organic anion transporting polypeptide 1c1-mediated thyroxine transport by the fenamate class of nonsteroidal antiinflammatory drugs. Endocrinology. 2009 Feb;150(2):1025-32. doi: 10.1210/en.2008-0188. Epub 2008 Oct 9. [PubMed:18845642]
- Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [PubMed:10592235]
Drug created on June 13, 2005 07:24 / Updated on March 02, 2018 05:17